Northwest Biotherapeutics, Inc.

Equities

NWBO

US66737P6007

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:15 2024-05-17 pm EDT			5-day change	1st Jan Change
0.4719 ^USD	-1.69%		-3.30%	-32.68%

May. 10	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	CI

Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 10, 2022 at 06:05 am EDT

Northwest Biotherapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.403 million compared to USD 0.239 million a year ago. Net loss was USD 14.21 million compared to USD 4.12 million a year ago. Basic loss per share from continuing operations was USD 0.01. Diluted loss per share from continuing operations was USD 0.01.

Latest news about Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	Mar. 21	CI
Northwest Biotherapeutics, Inc. Announces Retirement of Jerry Jasinowski from the Board of Directors	Mar. 14	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for Glioblastoma	Dec. 21	CI
Northwest Biotherapeutics, Inc. announced that it has received $11.005 million in funding from Streeterville Capital, LLC	Nov. 09	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory Board	23-09-12	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Transcript : Northwest Biotherapeutics, Inc. - Shareholder/Analyst Call	22-12-30
Northwest Biotherapeutics Sues Citadel Securities, Other Market Market Makers for Alleged Stock Price Manipulation	22-12-01	MT
Northwest Biotherapeutics Reports Positive Top-Line Results from Phase 3 Trial of DCVax®-L for Glioblastoma	22-11-17	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Northwest Biotherapeutics Files $250 Million Mixed Shelf	22-10-19	MT
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan by MHRA	22-08-23	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing At Sawston, Uk Facility	22-07-06	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-01	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-02-28	CI
Northwest Biotherapeutics Announces Commencement of Cancer Vaccine Production At Its Sawston, UK Facility	22-02-17	CI
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing at Sawston, UK Facility	21-12-21	CI

Chart Northwest Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Companyâs wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NORTHWEST BIOTHERAPEUTICS, INC.	-32.68%	581M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs